



December 16, 2021

2022 Plan Changes

The following changes will take effect January 1, 2022. Complete tier lists and prior authorization (PA) criteria can be found on our website at <https://oklahoma.gov/ohca/providers/types/pharmacy/pharmacy.html>. Pharmacy prior authorization forms can be found at <https://oklahoma.gov/ohca/providers/forms/rxforms.html>.

Anticonvulsants

- Epidiolex® will require previous trials with at least 3 anticonvulsants for the diagnosis of Lennox-Gastaut syndrome (LGS) or Tuberous sclerosis complex (TSC)-associated seizures or previous trial with at least 1 anticonvulsant for the diagnosis of Dravet syndrome, in addition to the current PA criteria. Members currently stable on Epidiolex® will be approved for continuation of therapy.

Anti-Diabetic Medications

- Trijardy® XR will move from special PA to Tier-2.

Attention-Deficit/Hyperactivity Disorder (ADHD) Medications

- Methylphenidate ER (generic Concerta®) will move from Tier-2 to Tier-1.
- Aptensio XR® will move from Tier-3 to Tier-2.
- Quillivant XR® will move from Tier-3 to Tier-2.
- Dyanavel® XR will move from special PA to Tier-2.
- Qelbree® will move from Tier-3 to Tier-2 and will require 2 Tier-1 trials.
- Vyvanse® chewable tablets and QuilliChew ER® will move from Tier-1 to special PA.
 - Note: Vyvanse® chewable tablets and QuilliChew ER® will no longer be preferred, and members currently on these medications will need to switch to either Vyvanse® capsules, a Tier-1 long-acting methylphenidate capsule (i.e., methylphenidate CD or methylphenidate LA), or another available Tier-1 medication, all of which do not require PA. If there is a patient-specific, clinically significant reason the member needs to remain on current therapy with Vyvanse® chewable tablets or QuilliChew ER®, a PA form must be submitted documenting the clinically significant information.
 - If appropriate to switch therapy, current Tier-1 long-acting stimulant medications available without PA and which can be used for members who cannot swallow capsules/tablets include Daytrana® patches; Vyvanse® capsules which can be opened and dissolved in a glass of water or orange juice or mixed with yogurt; amphetamine/dextroamphetamine ER, brand Focalin XR®, methylphenidate CD, and methylphenidate LA capsules which can all be opened and sprinkled onto applesauce.
- Special formulations (e.g., Daytrana® patches, Dyanavel® XR, Quillivant XR®, Vyvanse® chewable tablets, QuilliChew ER®) have an age restriction of 10 years of age and younger. Members older than 10 years of age will require a reason why a special formulation product is needed.

Gonadotropin-Releasing Hormone (GnRH) Medications

- Fensolvi® will move from Tier-3 to Tier-1.

Chronic Hepatitis C Virus (HCV) Medications

- Mavyret® tablets and generic sofosbuvir/velpatasvir tablets remain the preferred direct-acting antiviral (DAA) medications for the treatment of chronic HCV.
- Mavyret® oral pellets will be preferred for pediatric members 3 years to 11 years of age.
- Harvoni® 45mg/200mg oral tablets will no longer be preferred for pediatric members.

Nausea/Vomiting in Pregnancy

- Bonjesta® will be available without a PA.

Ophthalmic Antibiotic/Steroid Combination Products

- Tobradex® ST will move from Tier-2 to Tier-1.

Targeted Immunomodulator Agents

- Kineret®, Otezla®, and Rituxan® will move from Tier-3 to Tier-2.

Thank you for the services you provide to Oklahomans insured by SoonerCare!

SOONERCARE PHARMACY SERVICES • PHARMACY MANAGEMENT CONSULTANTS



ADDRESS

4345 N. Lincoln Blvd.
Oklahoma City, OK 73105



WEBSITES

oklahoma.gov/ohca
mysoonerCare.org



PHONE

Admin: 405-522-7300
Helpline: 800-987-7767